ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinalni stromalni tumorji - antineoplastična sredstva - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - prosimo, glejte dokument o izdelku.

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - acitretin - kapsula, trda - acitretin 25 mg / 1 kapsula - acitretin

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - acitretin - kapsula, trda - acitretin 10 mg / 1 kapsula - acitretin

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastična sredstva - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

baxter holding b.v. - doksorubicinijev klorid - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastična sredstva - caelyx pegylated liposomal je navedeno:kot monotherapy za bolnike z metastatskim rakom dojke, kjer je povečana srčna tveganja;za zdravljenje advanced rak na jajčnikih pri ženskah, ki niso uspeli v prvi vrstici platinum, ki temelji kemoterapijo režim;v kombinaciji z bortezomib za zdravljenje postopno več plazmocitom pri bolnikih, ki so prejeli vsaj en pred terapijo in ki so že obdelani ali ki so neprimerni za presaditev kostnega mozga;za zdravljenje hiv kaposi ' s sarkom (ks) pri bolnikih z nizko cd4 šteje (.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

ipsen pharma - cabozantinib - Širokopasemske neoplazme - antineoplastična sredstva - zdravljenje odraslih bolnikov s progresivnim, neresektabilnim lokalno napredovalim ali metastatskim medularnim karcinomom ščitnice.

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mitomicin - prašek za intravezikalno raztopino/raztopino za injiciranje - mitomicin 1 mg / 1 ml - mitomicin

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mitomicin - prašek za intravezikalno raztopino/raztopino za injiciranje - mitomicin 1 mg / 1 ml - mitomicin

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mitomicin - prašek za intravezikalno raztopino/raztopino za injiciranje - mitomicin 1 mg / 1 ml - mitomicin